{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-344748","form_type":"8-K","ticker":"SEER","cik":"0001726445","company_name":"Seer, Inc.","filed_at":"2026-08-11T20:23:00+00:00","discovered_at":"2026-08-11T20:24:01.384406+00:00","generated_at":"2026-08-11T20:24:06.181381+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Seer Q2 2026 revenue down 23% to $3.1M; net loss $16.9M; reaffirms FY26 guidance","bullets":["Revenue $3.1M vs $4.1M in Q2 2025, a 23% decline on macro headwinds and longer sales cycles.","Net loss narrowed to $16.9M from $19.4M; operating expenses fell 19% to $18.3M.","Cash, equivalents and investments ~$209.5M at June 30, 2026; repurchased ~200,000 shares.","Reaffirms FY2026 revenue guidance of $16M-$18M, implying ~3% growth at midpoint.","Initiated ITC investigation against Nanomics for alleged patent infringement on Proteograph."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-344748","json":"https://secwatch.observer/filing/0001193125-26-344748.json","markdown":"https://secwatch.observer/filing/0001193125-26-344748.md","text":"https://secwatch.observer/filing/0001193125-26-344748.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1726445/000119312526344748/0001193125-26-344748-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1726445/000119312526344748/ck0001726445-20260811.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-11T20:24:06.181381+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}